130 related articles for article (PubMed ID: 22236913)
1. Managing malaria in tuberculosis patients on fluoroquinolone-containing regimens: assessing the risk of QT prolongation.
Murphy ME; Singh KP; Laurenzi M; Brown M; Gillespie SH
Int J Tuberc Lung Dis; 2012 Feb; 16(2):144-9, i-iii. PubMed ID: 22236913
[TBL] [Abstract][Full Text] [Related]
2. Arrhythmias associated with fluoroquinolone therapy.
Falagas ME; Rafailidis PI; Rosmarakis ES
Int J Antimicrob Agents; 2007 Apr; 29(4):374-9. PubMed ID: 17241772
[TBL] [Abstract][Full Text] [Related]
3. QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications.
Briasoulis A; Agarwal V; Pierce WJ
Cardiology; 2011; 120(2):103-10. PubMed ID: 22156660
[TBL] [Abstract][Full Text] [Related]
4. Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens.
Ho CC; Chen YC; Hu FC; Yu CJ; Yang PC; Luh KT
Clin Infect Dis; 2009 Jun; 48(11):1526-33. PubMed ID: 19400686
[TBL] [Abstract][Full Text] [Related]
5. [Ventricular arrhythmias. A potential risk associated with the use of non-cardiovascular drugs prolonging the QT interval].
Calderone V; Cavero I
Minerva Med; 2002 Jun; 93(3):181-97. PubMed ID: 12094149
[TBL] [Abstract][Full Text] [Related]
6. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic agents associated with QT interval prolongation.
Olsen KM
J Fam Pract; 2005 Jun; Suppl():S8-S14. PubMed ID: 15938993
[TBL] [Abstract][Full Text] [Related]
8. Takotsubo cardiomyopathy and QT interval prolongation: who are the patients at risk for torsades de pointes?
Samuelov-Kinori L; Kinori M; Kogan Y; Swartzon M; Shalev H; Guy D; Ferenidou F; Mashav N; Sadeh B; Atzmony L; Kliuk-Ben-Basat O; Steinvil A; Justo D
J Electrocardiol; 2009; 42(4):353-357.e1. PubMed ID: 19261294
[TBL] [Abstract][Full Text] [Related]
9. QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines.
Arbel Y; Swartzon M; Justo D
Anticancer Drugs; 2007 Apr; 18(4):493-8. PubMed ID: 17351403
[TBL] [Abstract][Full Text] [Related]
10. Management of drug-resistant tuberculosis.
Chiang CY; Schaaf HS
Int J Tuberc Lung Dis; 2010 Jun; 14(6):672-82. PubMed ID: 20487603
[TBL] [Abstract][Full Text] [Related]
11. QT interval prolongation and torsades de pointes due to erythromycin lactobionate.
Oberg KC; Bauman JL
Pharmacotherapy; 1995; 15(6):687-92. PubMed ID: 8602374
[TBL] [Abstract][Full Text] [Related]
12. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].
Ames D; Camm J; Cook P; Falkai P; Gury C; Hurley R; Johnson G; Piepho R; Vieweg V;
Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268
[TBL] [Abstract][Full Text] [Related]
13. Drug-induced long QT syndrome and torsade de pointes.
Morissette P; Hreiche R; Turgeon J
Can J Cardiol; 2005 Aug; 21(10):857-64. PubMed ID: 16107909
[TBL] [Abstract][Full Text] [Related]
14. Torsades de pointes associated with fluoroquinolones: importance of concomitant risk factors.
Amankwa K; Krishnan SC; Tisdale JE
Clin Pharmacol Ther; 2004 Mar; 75(3):242-7. PubMed ID: 15001976
[TBL] [Abstract][Full Text] [Related]
15. QT prolongation and development of torsades de pointes with the concomitant administration of oral erythromycin base and quinidine.
Lin JC; Quasny HA
Pharmacotherapy; 1997; 17(3):626-30. PubMed ID: 9165570
[TBL] [Abstract][Full Text] [Related]
16. Drug-induced QT prolongation and proarrhythmia: an inevitable link?
Ahmad K; Dorian P
Europace; 2007 Sep; 9 Suppl 4():iv16-22. PubMed ID: 17766320
[TBL] [Abstract][Full Text] [Related]
17. Sex differences in ventricular repolarization: from cardiac electrophysiology to Torsades de Pointes.
Abi-Gerges N; Philp K; Pollard C; Wakefield I; Hammond TG; Valentin JP
Fundam Clin Pharmacol; 2004 Apr; 18(2):139-51. PubMed ID: 15066127
[TBL] [Abstract][Full Text] [Related]
18. Frequency of high-risk use of QT-prolonging medications.
Allen LaPointe NM; Curtis LH; Chan KA; Kramer JM; Lafata JE; Gurwitz JH; Raebel MA; Platt R
Pharmacoepidemiol Drug Saf; 2006 Jun; 15(6):361-8. PubMed ID: 16178046
[TBL] [Abstract][Full Text] [Related]
19. Safety concerns with fluoroquinolones.
Mehlhorn AJ; Brown DA
Ann Pharmacother; 2007 Nov; 41(11):1859-66. PubMed ID: 17911203
[TBL] [Abstract][Full Text] [Related]
20. Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation?
Mayet S; Gossop M; Lintzeris N; Markides V; Strang J
Drug Alcohol Rev; 2011 Jul; 30(4):388-96. PubMed ID: 21355918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
